Pear Therapeutics (PEAR) Gets a Hold From BTIG
Pear Extends Selloff as Downgrades Follow Strategic Shake-up
Credit Suisse Downgrades Pear Therapeutics to Neutral, Lowers Price Target to $1
Pear Therapeutics (PEAR) Was Downgraded to a Hold Rating at BTIG
Chardan Trims Price Target on Pear Therapeutics to $8 From $9 on Headcount Reduction, Reiterates Buy Rating
Pear Therapeutics (PEAR) Receives a Buy From BTIG
No Data